Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.

Prudner BC, Rathore R, Robinson AM, Godec AJ, Chang SF, Hawkins WG, Hirbe AC, Van Tine BA.

Clin Cancer Res. 2019 May 21. pii: clincanres.0206.2019. doi: 10.1158/1078-0432.CCR-19-0206. [Epub ahead of print]

PMID:
31113844
2.

Challenges in IBD Research: Pragmatic Clinical Research.

Scott FI, Rubin DT, Kugathasan S, Bousvaros A, Elson CO, Newberry RD, Melmed GY, Pekow J, Fleshman JW, Boyle BM, Mahadevan U, Cannon LM, Long MD, Cross RK, Ha CY, Lasch KL, Robinson AM, Rafferty JF, Lee JJ, Dahl KDC, Weaver A, Shtraizent N, Honig G, Hurtado-Lorenzo A, Heller CA.

Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S40-S47. doi: 10.1093/ibd/izz085.

PMID:
31095704
3.

OPTN/SRTR 2017 Annual Data Report: Heart.

Colvin M, Smith JM, Hadley N, Skeans MA, Uccellini K, Lehman R, Robinson AM, Israni AK, Snyder JJ, Kasiske BL.

Am J Transplant. 2019 Feb;19 Suppl 2:323-403. doi: 10.1111/ajt.15278.

PMID:
30811894
4.

OPTN/SRTR 2017 Annual Data Report: Liver.

Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Noreen SM, Robinson AM, Miller E, Snyder JJ, Israni AK, Kasiske BL.

Am J Transplant. 2019 Feb;19 Suppl 2:184-283. doi: 10.1111/ajt.15276.

PMID:
30811890
5.

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

Loftus EV Jr, Reinisch W, Panaccione R, Berg S, Alperovich G, Bereswill M, Kalabic J, Petersson J, Thakkar R, Robinson AM, D'Haens G.

Inflamm Bowel Dis. 2019 Feb 8. doi: 10.1093/ibd/izz008. [Epub ahead of print]

PMID:
30753510
6.

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF.

J Crohns Colitis. 2019 May 27;13(6):725-734. doi: 10.1093/ecco-jcc/jjy223.

7.

The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.

Hyams JS, Dubinsky M, Rosh J, Ruemmele FM, Eichner SF, Maa JF, Lazar A, Alperovich G, Mostafa NM, Robinson AM.

Aliment Pharmacol Ther. 2019 Jan;49(2):155-164. doi: 10.1111/apt.15054. Epub 2018 Dec 2.

PMID:
30506693
8.

Association between the North Carolina Medical Board opioid guideline update and opioid prescriptions in Medicare Part D beneficiaries.

Gillette C, Bush MA, Rogers KML, Mospan G, Nealy K, DeGeeter M, Robinson AM.

J Opioid Manag. 2018 Jul/Aug;14(4):239-243. doi: 10.5055/jom.2018.0455.

PMID:
30234920
9.

Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.

Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson AM, Singh RSP, Mostafa NM, Suzuki Y, Hibi T.

Inflamm Intest Dis. 2018 Jul;2(4):228-235. doi: 10.1159/000486786. Epub 2018 May 15.

10.

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO.

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671-680. doi: 10.1016/S2468-1253(18)30233-4. Epub 2018 Jul 25.

11.

Targeting eotaxin-1 and CCR3 receptor alleviates enteric neuropathy and colonic dysfunction in TNBS-induced colitis in guinea pigs.

Filippone RT, Robinson AM, Jovanovska V, Stavely R, Apostolopoulos V, Bornstein JC, Nurgali K.

Neurogastroenterol Motil. 2018 Nov;30(11):e13391. doi: 10.1111/nmo.13391. Epub 2018 Jul 3.

PMID:
29968270
12.

Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2.

Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, Eichner S, Maa JF, Alperovich G, Robinson AM, Hyams JS.

J Crohns Colitis. 2018 Nov 9;12(10):1249-1254. doi: 10.1093/ecco-jcc/jjy087.

13.

Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.

DʼHaens G, Reinisch W, Panaccione R, Satsangi J, Petersson J, Bereswill M, Arikan D, Perotti E, Robinson AM, Kalabic J, Alperovich G, Thakkar R, Loftus EV.

Am J Gastroenterol. 2018 Jun;113(6):872-882. doi: 10.1038/s41395-018-0098-4. Epub 2018 Jun 5.

PMID:
29867173
14.

Measuring and monitoring equity in access to deceased donor kidney transplantation.

Stewart DE, Wilk AR, Toll AE, Harper AM, Lehman RR, Robinson AM, Noreen SA, Edwards EB, Klassen DK.

Am J Transplant. 2018 Aug;18(8):1924-1935. doi: 10.1111/ajt.14922. Epub 2018 Jun 1.

PMID:
29734498
15.

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.

Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM.

J Crohns Colitis. 2018 Jul 30;12(8):930-938. doi: 10.1093/ecco-jcc/jjy050.

16.

Clinical disease activity in the CALM study - Authors' reply.

Colombel JF, Panaccione R, Petersson J, Robinson AM, D'Haens G.

Lancet. 2018 Apr 14;391(10129):1482. doi: 10.1016/S0140-6736(18)30775-X. No abstract available.

PMID:
29676280
17.

Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.

Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa JF, Wallace K, Lacerda A, Thakkar RB, Robinson AM.

Inflamm Bowel Dis. 2018 Apr 23;24(5):932-942. doi: 10.1093/ibd/izx082.

PMID:
29668919
18.

Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies.

Louis EJ, Reinisch W, Schwartz DA, Löfberg R, Robinson AM, Berg S, Wang AW, Maa JF, Huang B, Pappalardo B.

Adv Ther. 2018 Apr;35(4):563-576. doi: 10.1007/s12325-018-0678-0. Epub 2018 Mar 7.

19.

Exercise as a Prevention for Substance Use Disorder: A Review of Sex Differences and Neurobiological Mechanisms.

Lynch WJ, Robinson AM, Abel J, Smith MA.

Curr Addict Rep. 2017 Dec;4(4):455-466. doi: 10.1007/s40429-017-0178-3. Epub 2017 Nov 2.

20.

Exercise as a Sex-Specific Treatment for Substance Use Disorder.

Lynch WJ, Abel J, Robinson AM, Smith MA.

Curr Addict Rep. 2017 Dec;4(4):467-481. doi: 10.1007/s40429-017-0177-4. Epub 2017 Oct 23.

21.

Risk of ESRD in prior living kidney donors.

Wainright JL, Robinson AM, Wilk AR, Klassen DK, Cherikh WS, Stewart DE.

Am J Transplant. 2018 May;18(5):1129-1139. doi: 10.1111/ajt.14678. Epub 2018 Mar 8.

22.

Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.

Redlich N, Robinson AM, Nickel KP, Stein AP, Wheeler DL, Adkins DR, Uppaluri R, Kimple RJ, Van Tine BA, Michel LS.

Cell Death Dis. 2018 Jan 5;9(1):5. doi: 10.1038/s41419-017-0029-0.

23.

Traditional lecture versus jigsaw learning method for teaching Medication Therapy Management (MTM) core elements.

Wilson JA, Pegram AH, Battise DM, Robinson AM.

Curr Pharm Teach Learn. 2017 Nov;9(6):1151-1159. doi: 10.1016/j.cptl.2017.07.028. Epub 2017 Oct 28.

PMID:
29233385
24.

Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.

Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H.

Aliment Pharmacol Ther. 2018 Jan;47(2):219-228. doi: 10.1111/apt.14420. Epub 2017 Nov 21.

PMID:
29159817
25.

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G.

Lancet. 2018 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31. Erratum in: Lancet. 2018 Dec 23;390(10114):2768.

PMID:
29096949
26.

Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.

Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J.

J Crohns Colitis. 2017 Oct 27;11(11):1317-1325. doi: 10.1093/ecco-jcc/jjx093.

27.

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial.

Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson AM, Thakkar RB, Hibi T.

Intest Res. 2017 Jul;15(3):395-401. doi: 10.5217/ir.2017.15.3.395. Epub 2017 Jun 12.

28.

Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit.

Thong KY, Yadagiri M, Barnes DJ, Morris DS, Chowdhury TA, Chuah LL, Robinson AM, Bain SC, Adamson KA, Ryder REJ; ABCD Nationwide Dapagliflozin Audit contributors.

Prim Care Diabetes. 2018 Feb;12(1):45-50. doi: 10.1016/j.pcd.2017.06.004. Epub 2017 Jun 29.

PMID:
28669625
29.

The effects of social contact on cocaine intake in female rats.

Robinson AM, Fronk GE, Zhang H, Tonidandel S, Smith MA.

Drug Alcohol Depend. 2017 Aug 1;177:48-53. doi: 10.1016/j.drugalcdep.2017.03.027. Epub 2017 May 24.

30.

The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis.

Robinson AM, Rahman AA, Miller S, Stavely R, Sakkal S, Nurgali K.

Stem Cell Res Ther. 2017 Apr 18;8(1):87. doi: 10.1186/s13287-017-0540-3.

31.

Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.

Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G.

Am J Gastroenterol. 2017 Jun;112(6):975. doi: 10.1038/ajg.2017.120. Epub 2017 Apr 18. No abstract available.

PMID:
28417993
32.

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M.

J Gastroenterol. 2017 Sep;52(9):1079. doi: 10.1007/s00535-017-1340-3. No abstract available.

PMID:
28405767
33.

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M.

J Gastroenterol. 2017 Sep;52(9):1031-1040. doi: 10.1007/s00535-017-1325-2. Epub 2017 Mar 20. Erratum in: J Gastroenterol. 2017 Sep;52(9):1079.

34.

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease.

Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A.

Inflamm Bowel Dis. 2017 Mar;23(3):453-460. doi: 10.1097/MIB.0000000000001021.

35.

A comparison of the health benefits of reduced-exertion high-intensity interval training (REHIT) and moderate-intensity walking in type 2 diabetes patients.

Ruffino JS, Songsorn P, Haggett M, Edmonds D, Robinson AM, Thompson D, Vollaard NB.

Appl Physiol Nutr Metab. 2017 Feb;42(2):202-208. doi: 10.1139/apnm-2016-0497. Epub 2016 Oct 28.

PMID:
28121184
36.

The rapid detection of cefotaxime-resistant Enterobacteriaceae by HPLC.

Robinson AM, Medlicott NJ, Ussher JE.

Future Sci OA. 2016 Sep 9;2(4):FSO142. doi: 10.4155/fsoa-2016-0042. eCollection 2016 Dec.

37.

Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.

Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G.

Am J Gastroenterol. 2017 Oct;112(10):1584-1592. doi: 10.1038/ajg.2016.580. Epub 2017 Jan 10. Erratum in: Am J Gastroenterol. 2017 Jun;112(6):975.

PMID:
28071654
38.

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.

Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB.

Aliment Pharmacol Ther. 2017 Jan;45(1):50-62. doi: 10.1111/apt.13838. Epub 2016 Nov 7.

39.

The Effects of Excitatory and Inhibitory Social Cues on Cocaine-Seeking Behavior.

Smith MA, Zhang H, Robinson AM.

Front Behav Neurosci. 2016 Nov 9;10:217. eCollection 2016.

40.

Alterations of colonic function in the Winnie mouse model of spontaneous chronic colitis.

Robinson AM, Rahman AA, Carbone SE, Randall-Demllo S, Filippone R, Bornstein JC, Eri R, Nurgali K.

Am J Physiol Gastrointest Liver Physiol. 2017 Jan 1;312(1):G85-G102. doi: 10.1152/ajpgi.00210.2016. Epub 2016 Nov 23.

41.

Fecal Microbiota and Metabolome in a Mouse Model of Spontaneous Chronic Colitis: Relevance to Human Inflammatory Bowel Disease.

Robinson AM, Gondalia SV, Karpe AV, Eri R, Beale DJ, Morrison PD, Palombo EA, Nurgali K.

Inflamm Bowel Dis. 2016 Dec;22(12):2767-2787.

PMID:
27824648
42.

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.

Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R.

J Crohns Colitis. 2017 Apr 1;11(4):425-434. doi: 10.1093/ecco-jcc/jjw178.

43.

Acute bouts of wheel running decrease cocaine self-administration: Influence of exercise output.

Smith MA, Fronk GE, Zhang H, Magee CP, Robinson AM.

Pharmacol Biochem Behav. 2016 Nov - Dec;150-151:94-99. doi: 10.1016/j.pbb.2016.10.001. Epub 2016 Oct 5.

44.

Using synchrotron X-ray phase-contrast micro-computed tomography to study tissue damage by laser irradiation.

Robinson AM, Stock SR, Soriano C, Xiao X, Richter CP.

Lasers Surg Med. 2016 Nov;48(9):866-877. doi: 10.1002/lsm.22571. Epub 2016 Aug 23.

PMID:
27551862
45.

Rectal prolapse in Winnie mice with spontaneous chronic colitis: changes in intrinsic and extrinsic innervation of the rectum.

Rahman AA, Robinson AM, Brookes SJH, Eri R, Nurgali K.

Cell Tissue Res. 2016 Nov;366(2):285-299. doi: 10.1007/s00441-016-2465-z. Epub 2016 Aug 1.

PMID:
27477670
46.

Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases.

Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B.

Inflamm Bowel Dis. 2016 Nov;22(11):2711-2723. Review.

PMID:
27585411
47.

Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice.

McQuade RM, Carbone SE, Stojanovska V, Rahman A, Gwynne RM, Robinson AM, Goodman CA, Bornstein JC, Nurgali K.

Br J Pharmacol. 2016 Dec;173(24):3502-3521. doi: 10.1111/bph.13646. Epub 2016 Nov 16.

48.

Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.

Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD.

Am J Gastroenterol. 2016 Dec;111(12):1806-1815. doi: 10.1038/ajg.2016.433. Epub 2016 Sep 27.

PMID:
27670599
49.

Who is distressed? A comparison of psychosocial stress in pregnancy across seven ethnicities.

Robinson AM, Benzies KM, Cairns SL, Fung T, Tough SC.

BMC Pregnancy Childbirth. 2016 Aug 11;16(1):215. doi: 10.1186/s12884-016-1015-8.

50.

The effects of social contact on cocaine intake under extended-access conditions in male rats.

Robinson AM, Lacy RT, Strickland JC, Magee CP, Smith MA.

Exp Clin Psychopharmacol. 2016 Aug;24(4):285-96. doi: 10.1037/pha0000078.

Supplemental Content

Loading ...
Support Center